Sarah Harten's Biography

Sarah Harten, Senior Research Officer, Queensland Institute of Medical Research

Dr Harten, an NHMRC Early Career Research Fellow at the QIMR Berghofer Medical Research Institute in Brisbane, Australia. In 2010 she returned to Australia to join the laboratory of epigenetics expert Prof. Emma Whitelaw, to work on a mouse ENU mutagenesis screen aimed at identifying novel epigenetic modifiers. The screen produced a panel of over 40 mutant mouse lines with defects in both known and novel epigenetic modifiers. Homozygous mutants from several of the mutant lines display developmental heart defects. Dr Harten’s team is now investigating the role of epigenetics in cardiac development and adult on-set heart disease

An ENU mutagenesis screen identifies the first mouse mutants of a novel epigenetic modifier, Rearranged L-Myc Fusion (Rlf).

Tuesday, 4 September 2012 at 17:00

Add to Calendar ▼2012-09-04 17:00:002012-09-04 18:00:00Europe/LondonAn ENU mutagenesis screen identifies the first mouse mutants of a novel epigenetic modifier, Rearranged L-Myc Fusion (Rlf).SELECTBIOenquiries@selectbiosciences.com

A mutagenesis screen, using mice carrying an epigenetically sensitive GFP reporter was established to identify genes involved in epigenetic reprogramming. So far, over 50 mutant lines have been produced, including both well-known epigenetic genes e.g. Dnmt1 and novel genes e.g.Rlf.

Add to Calendar ▼2012-09-04 00:00:002012-09-05 00:00:00Europe/LondonEpigenetics EuropeSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors